A phase II clinical trial (NCT03512275) was subsequently designed to evaluate the safety, tolerability, and efficacy of 400 mg weekly for 13 consecutive weeks (week 0 to week 12) in patients with moderate-to-severe HS who had previously failed anti-TNF treatment (group A) and those who were naïve to anti-TNF therapy (group B) [6]. The gene discussed is TNF; the disease is histiocytic sarcoma.